| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway
|
Wang, Deli
|
|
|
89 |
1 |
p. 31-40
|
artikel
|
| 2 |
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis
|
Mukozu, Takanori
|
|
|
89 |
1 |
p. 11-20
|
artikel
|
| 3 |
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
|
Padda, Sukhmani K.
|
|
|
89 |
1 |
p. 105-115
|
artikel
|
| 4 |
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies
|
Tan, Antoinette R.
|
|
|
89 |
1 |
p. 49-58
|
artikel
|
| 5 |
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib
|
Tosca, E. M.
|
|
|
89 |
1 |
p. 117-128
|
artikel
|
| 6 |
Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis
|
Zhang, Qian
|
|
|
89 |
1 |
p. 1-9
|
artikel
|
| 7 |
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms
|
Yoshida, Keishi
|
|
|
89 |
1 |
p. 83-91
|
artikel
|
| 8 |
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers
|
Chen, Xue
|
|
|
89 |
1 |
p. 141-148
|
artikel
|
| 9 |
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants
|
Hibma, Jennifer E.
|
|
|
89 |
1 |
p. 71-81
|
artikel
|
| 10 |
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury
|
Heuschkel, Sandra
|
|
|
89 |
1 |
p. 41-48
|
artikel
|
| 11 |
4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent
|
Hufnagel, Stephanie
|
|
|
89 |
1 |
p. 59-69
|
artikel
|
| 12 |
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
|
Ide, Takafumi
|
|
|
89 |
1 |
p. 129-140
|
artikel
|
| 13 |
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis
|
Li, Chenggang
|
|
|
89 |
1 |
p. 149
|
artikel
|
| 14 |
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial
|
Patnaik, Amita
|
|
|
89 |
1 |
p. 93-103
|
artikel
|
| 15 |
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study
|
Ichimura, Takenori
|
|
|
89 |
1 |
p. 21-30
|
artikel
|
Tijdschrift beschrijving